Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Inventory (2022 - 2024)

Amylyx Pharmaceuticals has reported Change in Inventory over the past 3 years, most recently at $9.3 million for Q1 2024.

  • Quarterly results put Change in Inventory at $9.3 million for Q1 2024, down 30.44% from a year ago — trailing twelve months through Dec 2024 was $9.3 million (down 87.35% YoY), and the annual figure for FY2024 was $9.3 million, down 87.35%.
  • Change in Inventory for Q1 2024 was $9.3 million at Amylyx Pharmaceuticals, down from $26.5 million in the prior quarter.
  • Over the last five years, Change in Inventory for AMLX hit a ceiling of $26.5 million in Q4 2023 and a floor of $9.2 million in Q4 2022.
  • Median Change in Inventory over the past 3 years was $13.7 million (2023), compared with a mean of $15.3 million.
  • Biggest five-year swings in Change in Inventory: soared 187.65% in 2023 and later tumbled 30.44% in 2024.
  • Amylyx Pharmaceuticals' Change in Inventory stood at $9.2 million in 2022, then soared by 187.65% to $26.5 million in 2023, then tumbled by 65.06% to $9.3 million in 2024.
  • The last three reported values for Change in Inventory were $9.3 million (Q1 2024), $26.5 million (Q4 2023), and $14.0 million (Q3 2023) per Business Quant data.